Outlook Therapeutics (OTLK) Return on Invested Capital (2016 - 2025)

Outlook Therapeutics (OTLK) has reported Return on Invested Capital for 10 consecutive years, with 0.01% the latest figure, recorded in Q3 2025.

• In Q3 2025, Return on Invested Capital changed 0.0% year-over-year to 0.01%; the TTM figure through Sep 2025 stood at 0.01% (changed 0.0% YoY), while the FY2025 annual figure was 0.02%, up 3.0% from the prior year.
• Return on Invested Capital held at 0.01% in Q3 2025 per OTLK's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.01% in Q2 2024 and bottomed at 0.06% in Q1 2021.
• Historically, Return on Invested Capital has averaged 0.01% across 5 years, with a median of 0.01% in 2023.
• Annual changes were most pronounced in 2021 — Return on Invested Capital climbed 5 bps — and 2023, when it changed 0 bps.
• Outlook Therapeutics' Return on Invested Capital stood at 0.02% in 2021, then surged by 44 bps to 0.01% in 2022, then jumped by 39 bps to 0.01% in 2023, then rose by 24 bps to 0.01% in 2024, then slumped by 37 bps to 0.01% in 2025.
• Business Quant data shows OTLK's Return on Invested Capital at 0.01% in Q3 2025, 0.01% in Q2 2025, and 0.01% in Q1 2025.